Advanced Molecular Imaging & Therapy

11/25/2025

Big news: the transition is complete and AMIT is now officially part of the United Theranostics family!

Our name change brings with it a commitment to stronger patient support, expanded treatment capabilities, and a unified vision for compassionate, precision-driven cancer care.

To every patient, caregiver, and provider who trusts us: thank you.
To our new team members: welcome to the family — we’re honored to work with you.

Together, we’re building the future of radiopharmaceutical therapy.

09/12/2025

We are becoming United Theranostics.

Our new name represents our expansion into a national network of outpatient clinics, strengthening our ability to serve patients across the country.

As we complete this transition, you will begin to see updates to our name, branding, and communications.

What remains unchanged is our commitment to delivering the same expert, personalized care from the trusted team you know.

10/07/2024

Happy Nuclear Medicine Week!

10/01/2024

10/01/2023

Happy Nuclear Medicine Week! The hottest profession in healthcare!

04/02/2023

Pluvicto is currently only manufactured at a facility in Italy, the company said.

03/09/2023

https://amit.informz.net/informzdataservice/onlineversion/ind/bWFpbGluZ2luc3RhbmNlaWQ9ODk0MDMyMCZzdWJzY3JpYmVyaWQ9NzY3NTQ5NjE2

A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients, which is having a profound negative impact on patient care.1,2